雅虎香港 搜尋

登入

  1. 相關搜尋:

搜尋結果

  1. www.sanofi.comSanofi: global healthcare and pharmaceutical company

    2024年3月28日 · Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance. Read the Press Release. See all press releases. We are an innovative global healthcare company with one purpose: to chase the miracles of science to improve people’s lives.

  2. www.hkpcc.org.hk › sanofihongkongSanofi Hong Kong Limited | 香港家庭醫學學院

    BACK. Sanofi Hong Kong Limited. COMPANY INFORMATION. We chase the miracles of science to improve people’s lives. Our determination to find answers for patients motivates us to develop breakthrough medicines and vaccines. And to never settle.

  3. www.dnb.com › business-directory › company-profilesSanofi Hong Kong Limited Company Profile | Wong Chuk Hang, ...

    Find company research, competitor information, contact details & financial data for Sanofi Hong Kong Limited of Wong Chuk Hang. Get the latest business insights from Dun & Bradstreet.

  4. zh.wikipedia.org › wiki › 赛诺菲赛诺菲 - 维基百科，自由的百科全书簡

    赛诺菲 （法語： Sanofi ）总部位于 法国 巴黎 ，是 世界 上第五大的 制药 企业 [3] ，致力于医药产品的研究、开发、生产以及销售；产品主要覆盖七个领域： 心血管疾病 、 血栓 形成、 肿瘤学 、 糖尿病 、 中枢神经系统 、 内科 疾病和 疫苗 。 [4] 公司历史. 赛诺菲－安万特，由赛诺菲－圣德拉堡和安万特两家公司在2004年合并成立。 2004年年初，赛诺菲欲通过 恶意收购 的方式在股市并购市值被严重低估的安万特公司。 开始提出的并购方案为：公司名称保持赛诺菲原名，而新公司 董事会 全部由赛诺菲董事会成员构成。 由于并购方案本身的不合理性，此收购开始受到安万特公司的坚决抵制，其他公司如 诺华 也有意介入充当 白骑士 。

  5. www.scmp.com › business › banking-financeSanofi signs research tie-up with Hong Kong’s Insilico ...

    2022年11月9日 · Medicine. + FOLLOW. Iris Ouyang. + FOLLOW. Published: 4:23pm, 9 Nov 2022. Why you can trust SCMP. Sanofi has signed a strategic research collaboration with Hong Kong-based biotech firm...

  6. hk.linkedin.com › company › sanofiSanofi | LinkedIn

    About us. We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the...

  7. www.sanofi.com › en › media-roomPress Release: Sanofi and Innovent Biologics enter strategic ...

    2015年8月4日 · In addition to the strategic multi-product collaboration and license agreement, Sanofi, subject to conditions precedent including regulatory approval and customary closing conditions, will invest in new common shares issued by Innovent for €300 million, at a price of HK $42.42 per share, representing a 20% premium to the Innovent 30-trading-day ...

  1. 相關搜尋

    sanofi hong kong limited tel